Stock Monitor: Champions Oncology Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) ("Lexicon"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LXRX as the Company's latest news hit the wire. On March 26, 2018, the Company announced that in collaboration with Sanofi, the Company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotagliflozin, for use in combination with insulin therapy to improve glycemic control in adults with type-1 diabetes mellitus. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Champions Oncology, Inc. (NASDAQ: CSBR), which also belongs to the Healthcare sector as the Company Lexicon Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Lexicon Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
These Filings Highlight Lexicon's Strong Investment in Internally Discovered Therapies
Pablo Lapuerta, M.D., Executive Vice President and Chief Medical Officer of Lexicon, expressed that the NDA and MAA submissions for sotagliflozin represent important milestones for the Company and for people in the United States and Europe who are living with the challenges of type-1 diabetes. Pablo added that these filings highlight Lexicon's strong investment in internally discovered therapies and are a culmination of the largest Phase-3 program for an oral anti-diabetic agent ever conducted in type-1 diabetes, in the broadest range of patients, resulting in the most comprehensive efficacy and safety database.
Sotagliflozin potentially will be the first oral agent in the US to be used in combination with insulin to improve glycemic control and patient outcomes
Sanofi, Lexicon Diabetes License and Collaboration Deal
In November 2015, Sanofi and Lexicon entered into a collaboration and license agreement, pursuant to which Lexicon granted Sanofi an exclusive, worldwide (excluding Japan), royalty-bearing right and license to develop, manufacture, and commercialize sotagliflozin. Lexicon is responsible for all clinical development activities relating to type-1 diabetes and has exercised an exclusive option to co-promote and have a significant role, in collaboration with Sanofi, in the commercialization of sotagliflozin for the treatment of type-1 diabetes in the US Sanofi is responsible for all clinical development and commercialization of sotagliflozin for the treatment of type-2 diabetes worldwide (excluding Japan) and is solely responsible for the commercialization of sotagliflozin for the treatment of type-1 diabetes outside the US (excluding Japan).
About Type-1 Diabetes
Type-1 Diabetes is a chronic condition in which the pancreas produces little or no insulin. Insulin is a hormone needed to allow sugar (glucose) to enter cells to produce energy. Different factors, including genetics and some viruses, may contribute to Type 1 Diabetes. Although it usually appears during childhood or adolescence but can develop in adults. Its signs and symptoms can appear relatively suddenly and may include increased thirst, frequent urination, bed-wetting in children, extreme hunger, unintended weight loss, irritability, fatigue and weakness, and blurred vision.
Sotagliflozin (LX4211) is being developed by Lexicon for the treatment of type-1 and type-2 diabetes mellitus. Sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types-1 and-2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.
About Lexicon Pharmaceuticals, Inc.
Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.
Stock Performance Snapshot
March 27, 2018 - At Tuesday's closing bell, Lexicon Pharma's stock declined 1.80%, ending the trading session at $8.18.
Volume traded for the day: 415.80 thousand shares.
After yesterday's close, Lexicon Pharma's market cap was at $883.03 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.